Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
Authors: N. Harbeck, P.A. Fasching, R. Wuerstlein, T. Degenhardt, D. Lüftner, R.E. Kates, J. Schumacher, P. Räth, O. Hoffmann, R. Lorenz, T. Decker, M. Reinisch, T. Göhler, P. Staib, O. Gluz, T. Schinköthe, M. Schmidt, Dirk Günter Kieback, Marion Tina van Mackelenbergh, Carsten Hielscher, Mustafa Celalettin Ugur, Christoph Uleer, Mark-Oliver Zahn, Ralf Meyer, Susanne Kraudelt, Andrea Stefek, Daniel Pink, Marianne Just, Hans-Christian Kolberg, Tanja Fehm, Wolfram Malter, Mathias Warm, Helmut Forstbauer, Dirk Behringer, Anke Wortmann, Joachim Rom, Antje Lehnert, Sven Ackermann, Dagmar Guth, Eike Simon, Jan Dünnebacke, Arnd Hönig, Peter Ehscheidt, Karsten Gnauert, Thorsten Kühn, Ekkehard von Abel, Andreas Hartkopf, Ulrich Karck, Martina Negwer, Jürgen Wacker, Manfred Welslau, Jaqueline Sagasser, Bernhard Heinrichm, Cosima Brucker, Heribert Stauder, Isolde Gröll, Ricardo Felberbaum, Milos Popovic, Dirk-Toralf Baerens, Ulrike Söling, Matthias Zaiss, Jaqueline Rauh, Thomas Fietz, Jan Schröder, Hermann Voß, Johannes Mohm, Ute Neef, Lorenz Rieger, Andrea Distelrath, Arnd Nusch, Burkhard Schmidt, Kerstin Lüdtke-Heckenkamp, Michael Berghorn, Steffi Busch, Caroline Schock, Michael Metz, Andreas Lorenz, Jens Uhlig, Burkhard Otremba
Journal: Annals of Oncology (2023)

The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality of life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor or palbociclib + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is an interactive autonomous application reacting to patient self-reported observations.Between 2017 and 2021, 499 patients (median age 59 years) from 71 centers were randomized (2 : 1, stratified by therapy line) between an active version of CANKADO PRO-React (CANKADO-active arm) and a version with limited functionality (CANKADO-inform arm). A total of 412 patients (271 CANKADO-active; 141 CANKADO-inform) were available for analysis of the primary endpoint, time to deterioration (TTD) of QoL [10-point drop on the Functional Assessment of Cancer Therapy-General (FACT-G) score], using an Aalen-Johansen estimator for cumulative incidence function of TTD DQoL (QoL deterioration) with 95% pointwise confidence intervals (CIs). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and DQoL.In all patients [intention-to-treat (ITT)-ePRO], cumulative incidence of DQoL was significantly more favorable (lower) in the CANKADO-active arm (hazard ratio 0.698, 95% CI 0.506-0.963). Among first-line patients (n = 295), the corresponding hazard ratio was 0.716 (0.484-1.060; P = 0.09), and in second-line patients (n = 117) it was 0.661 (0.374-1.168; P = 0.2). Absolute patient numbers declined in later visits; FACT-G completion rates were 80% and higher until about visit 30. Mean FACT-G scores showed a steady decline from baseline and an offset in favor of CANKADO-active. No significant differences in clinical outcome were observed between arms: median PFS (ITT population) was 21.4 (95% CI 19.4-23.7) (CANKADO-active) and 18.7 (15.1-23.5) months (CANKADO-inform); median OS was not reached (CANKADO-active) and 42.6 months (CANKADO-inform).PreCycle is the first multicenter randomized eHealth trial demonstrating a significant benefit for MBC patients receiving oral tumor therapy when using an interactive autonomous patient empowerment application.